# Study of Out of Specification for Tisagenlecleucel

> **NCT04094311** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CTL019

## Key facts

- **NCT ID:** NCT04094311
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-21
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094311, "Study of Out of Specification for Tisagenlecleucel". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04094311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*